

# Anti-C-Raf (S471) [B-Raf (S579)/A-Raf (S432)], Phosphospecific Antibody

Catalog # AN1935

## Product Information

Application	WB
Primary Accession	<u>P04049</u>
Host	Rabbit
Clonality	Rabbit Polyclonal
Isotype	IgG
Calculated MW	73052

### **Additional Information**

Gene ID Other Names	5894 Raf1, CRaf
Dilution	WB~~1:1000
Storage	Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	Anti-C-Raf (S471) [B-Raf (S579)/A-Raf (S432)], Phosphospecific Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
Shipping	Blue Ice

### Background

The Ras-Raf-MAP kinase signaling pathway is involved in control of cell proliferation and differentiation. The Raf kinase family includes A-Raf, B-Raf, and C-Raf. Each family member has three highly conserved regions (CR1-3). The N-terminal CR1 contains the Ras-GTP-binding domain. The CR2 contains a negative regulatory serine residue (C-Raf (S259)/B-Raf(S365)) that may bind 14-3-3 proteins. The CR3 is the catalytic domain that contains phosphorylation sites for Raf-regulating enzymes within two segments, the N-region and the activation segment. Activation of C-Raf involves phosphorylation at many sites including Ser-338, Tyr-341, and Ser-471. The latter site is phosphorylated after EGF stimulation and may be important for MEK interaction in both C-Raf and A-Raf. In B-Raf, multiple phosphorylation sites have been identified, but their specific roles are uncertain. Phosphorylation of Ser-446 may prime B-Raf for activation, and Ser-446 and/or Ser-447 phosphorylation may be critical for B-Raf biological activity during PC12 differentiation. Ser-579 is required for growth factor activation and kinase activity.

### Images



& 3) or treated (lanes 2 & 4) with lambda phosphatase and probed with anti-C-Raf (N-terminal region) (lanes 1 & 2) or anti-C-Raf (Ser-471) (lanes 3 & 4).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.